Patients with inoperable , advanced imatinib-resistant GIST were randomized ( 1 : 1 ) to receive masitinib ( 12 mg/kg/day ) or sunitinib ( 50 mg/day 4-weeks-on/2-weeks-off ) until progression , intolerance , or refusal .